p16 overexpression: A potential early indicator of transformation in ovarian carcinoma

Journal of the Society for Gynecologic Investigation

Volumn 4, Issue 2, 1997, Pages 95-102

  Shigemasa, K ^a,b   Hu, C ^a,b   West, C M ^a,b   Clarke, J ^a,b   Parham, G P ^a,b   Parmley, T H ^a,b   Korourian, S ^a,b   Baker, V V ^a,b   O'Brien, T J ^a,b,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Slot 718   (United States)

Author keywords

mRNA expression; mutation status; ovarian cancer; p16

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN P16;

ARTICLE; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BLOTTING, WESTERN; CARCINOMA; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; OVARIAN NEOPLASMS; OVARY; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 0030903557     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(97)81110-0     Document Type: Article

References (16)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:182l-8.
2. Hunter T. Braking the cycle. Cell 1993;75:839-41.
3. Peter M, Herskowitz I. Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994;79:181-4.
4. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994; 54:6078-82.
5. psk-33/cdk4) for mammalian D type G1 cyclins. Cell 1992;71:323-34.
6. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
8. Kamb A, Gruis NA, Weaver-Feldhaus J. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
9. Nobori T, Miura K, We DJ, Lois A, Takabayashi K, Carson D. Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
10. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-6.
11. Spruck CH III, Gonzalez-Zulueta M, Shibata A, et al. p16 gene in uncultured tumors. Nature 1994;370:183-4.
12. INK4 mutations and altered expression in human tumors and cell lines. In: The molecular genetics of cancer. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1994:49-57.
13. Hall JL, Dudley L, Dobner PR, Lewis SA, Cowan NJ. Identification of two human β-tubulin isotypes. Mol Cell Biol 1983;3: 854-62.
14. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:7160-4.
15. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996;56:722-7.
16. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/ p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525-30.